| 39.485 0.435 (1.11%) | 01-09 15:55 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 47.67 | 1-year : | 55.68 |
| Resists | First : | 40.81 | Second : | 47.67 |
| Pivot price | 38.85 |
|||
| Supports | First : | 37.97 |
Second : | 36.21 |
| MAs | MA(5) : | 38.4 |
MA(20) : | 39.04  |
| MA(100) : | 31.29 |
MA(250) : | 24.52 |
|
| MACD | MACD : | 0.5 |
Signal : | 0.7 |
| %K %D | K(14,3) : | 76.3 |
D(3) : | 57.2 |
| RSI | RSI(14): 57.3 |
|||
| 52-week | High : | 40.81 | Low : | 13.42 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ BBC ] has closed below upper band by 34.3%. Bollinger Bands are 6.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 39.94 - 40.13 | 40.13 - 40.31 |
| Low: | 38.99 - 39.21 | 39.21 - 39.42 |
| Close: | 39.13 - 39.47 | 39.47 - 39.79 |
Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering ("lead drug") that is typically in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development, but prior to receiving marketing approval.
Sat, 10 Jan 2026
How Virtus Lifesci Biotech Clinical Trials Etf (BBC) Affects Rotational Strategy Timing - Stock Traders Daily
Fri, 09 Jan 2026
What's Going On With Alumis Stock Thursday? - Sahm
Thu, 08 Jan 2026
What's Going On With Alumis Stock Thursday? - Benzinga
Mon, 29 Dec 2025
(BBC) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Mon, 01 Dec 2025
Biotech ETF (BBC) Hits New 52-Week High - Zacks Investment Research
Tue, 25 Nov 2025
The Zacks Analyst Blog Highlights LLY, EPHE, BBC, HELX, XHS and SURI - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
AMEX
|
|
|
Sector:
Financial Services
|
|
|
Industry:
Asset Management
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|